ArticleAdvanced healthcare materials2026
Engineering Extracellular Vesicle Production Through Magnetic Ion Channel Activation for Bone Regeneration.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Refining the biomanufacturing of microalgae-derived extracellular vesicles as a potential nanotherapeutic for osteoarthritis.Regenerative biomaterials · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bone disorders represent a significant global health challenge. Extracellular Vesicles (EVs) are emerging as a promising nanotherapeutic approach for bone regeneration, addressing the translation barriers associated with cell-based therapies. Despite their immense potential, the clinical application of EVs is limited by low production yields and inconsistent quality. Magnetic Ion Channel Activation (MICA) leverages remote magnetic fields to stimulate mechano-sensitive ion channels through magnetic nanoparticles (MNPs). This study explores the potential of utilising MICA to enhance the production yield and therapeutic efficacy of EVs for bone regeneration. The findings demonstrate that MICA significantly increased the production yield of EVs from MC3T3 pre-osteoblasts compared to magnetic stimulation or TREK1 functionalised graphene oxide- -GOMNP particles alone. The obtained EVs exhibited typical size distribution, morphology, and EV protein expression, consistent with nano-sized vesicles. Furthermore, MICA/TREK EVs treatment considerably enhanced human bone marrow-derived mesenchymal stem cells (hBMSCs) osteogenic differentiation and mineralization compared to EVs derived from MICA, TREK, or untreated groups. Proteomics analysis revealed the enrichment of proteins involved in mechanotransduction and osteogenic differentiation within MICA/TREK EVs. In summary, these findings highlight the substantial potential of MICA as a platform to enhance the scalable production and therapeutic application of pro-regenerative EVs for bone augmentation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.